Despite the success of intravitreal anti-VEGF therapy in treating age-related macular degeneration, serious concerns abound over the potential burden of repeated injections. Although still in the early stages of development, candidate drug therapies could offer the theoretical potential of enhancing anti-VEGF efficacy and, perhaps, leading to...

A novel platelet-derived growth factor currently being studied in clinical trials may boost the effect of anti-VEGF therapy and provide a benefit in patients with choroidal neovascularization secondary to age-related macular degeneration, according to a speaker at the at Retina 2010 meeting. A phase 1 trial of E10030 (Ophthotech), a PDGF-B...

Ophthotech has received $30 million in Series B financing to support a phase 2 combination trial of E10030, the company's lead product candidate for treating age-related macular degeneration, the company announced. In a phase 1 combination study, E10030, an anti-platelet-derived growth factor (PDGF) aptamer, demonstrated effectiveness when...

Intravitreal Lucentis (ranibizumab) injections in patients with neovascular AMD results in decreased aqueous levels of VEGF and increased levels of platelet-derived growth factor (PDGF). Methods and results In this prospective clinical trial 28 eyes of patients with neovascular AMD were compared with 28 eyes of age-matched patients with...

Positive results of a phase 1 clinical study evaluating E10030, a novel anti-platelet derived growth factor (anti-PDGF) in conjunction with an anti-vascular endothelial growth factor (anti-VEGF), to treat wet age-related macular degeneration (wet AMD). Anti-PDGF therapy resulted in enhanced visual outcome and was associated with significant...